

Jennifer M Specht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7891428/publications.pdf>

Version: 2024-02-01

35
papers

1,862
citations

361413

20
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

2582
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 32-42.	2.4	4
2	¹⁸ F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2 ⁻ Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 184-190.	5.0	20
3	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. <i>Cancer Cell</i> , 2021, 39, 193-208.e10.	16.8	157
4	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	1.6	22
5	¹⁸ F-fluorodeoxyglucose (FDG) PET or ¹⁸ F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. <i>Breast Cancer Research</i> , 2021, 23, 88.	5.0	11
6	Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016. <i>Radiology</i> , 2021, 300, 290-300.	7.3	13
7	Facility Variability in Examination Indication Among Women With Prior Breast Cancer: Implications and the Need for Standardization. <i>Journal of the American College of Radiology</i> , 2020, 17, 755-764.	1.8	9
8	Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 255-268.	2.5	11
9	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	1.6	36
10	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer: A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. <i>Clinical Breast Cancer</i> , 2019, 19, e283-e296.	2.4	24
11	Test-Retest Reproducibility of ¹⁸ F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. <i>Journal of Nuclear Medicine</i> , 2019, 60, 608-614.	5.0	21
12	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e143-e149.	2.4	15
13	Prospective Study of Serial ¹⁸ F-FDG PET and ¹⁸ F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1823-1830.	5.0	41
14	Optimal duration of trastuzumab for early HER2-positive breast cancer. <i>Lancet</i> , 2017, 389, 1167-1168.	13.7	1
15	Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. <i>Clinical Breast Cancer</i> , 2015, 15, e277-e285.	2.4	6
16	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3840-3847.	1.6	253
17	A Phase 2 Study of ¹⁶ α-[¹⁸ F]-fluoro- ¹⁷ β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). <i>Molecular Imaging and Biology</i> , 2014, 16, 431-440.	2.6	80
18	Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004. <i>Clinical Cancer Research</i> , 2013, 19, 1884-1893.	7.0	38

#	ARTICLE	IF	CITATIONS
19	Circulating biomarkers in patients receiving neoadjuvant chemotherapy combined with sunitinib for locally advanced breast cancer.. Journal of Clinical Oncology, 2013, 31, 1089-1089.	1.6	8
20	A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC).. Journal of Clinical Oncology, 2013, 31, 1090-1090.	1.6	0
21	Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Research, 2012, 14, 206.	5.0	32
22	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Research, 2012, 2, 34.	2.5	27
23	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomographyâ€“Computed Tomography in Breast Cancer: Whenâ€” and When Not?. Journal of Clinical Oncology, 2012, 30, 1252-1254.	1.6	11
24	Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates.. Journal of Clinical Oncology, 2012, 30, TPS3109-TPS3109.	1.6	0
25	Quantitative measures of FDG PET after neoadjuvant chemotherapy to predict breast cancer patient survival.. Journal of Clinical Oncology, 2012, 30, 1088-1088.	1.6	0
26	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 4799-4805.	7.0	120
27	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. Clinical Cancer Research, 2011, 17, 2400-2409.	7.0	94
28	Association between serial dynamic contrast-enhanced MRI and dynamic ¹⁸ Fâ€“FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Magnetic Resonance Imaging, 2010, 32, 1124-1131.	3.4	41
29	Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer. Clinical Cancer Research, 2010, 16, 2803-2810.	7.0	72
30	Kinetic Analysis of ¹⁸ F-Fluoride PET Images of Breast Cancer Bone Metastases. Journal of Nuclear Medicine, 2010, 51, 521-527.	5.0	65
31	Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient. Clinical Cancer Research, 2009, 15, 5294-5296.	7.0	43
32	Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Seminars in Radiation Oncology, 2009, 19, 222-228.	2.2	51
33	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4449-4457.	1.6	142
34	Serial 2-[¹⁸ F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Research and Treatment, 2007, 105, 87-94.	2.5	97
35	Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases. Journal of Experimental Medicine, 1997, 186, 1213-1221.	8.5	297